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Clinical trials for orphan diseases are critical for developing effective therapies. One such condition, fibrodysplasia ossificans
progressiva (FOP; MIM#135100), is characterized by progressive heterotopic ossification (HO) that leads to severe disability.
Individuals with FOP are extremely sensitive to even minor traumatic events. There has been substantial recent interest in clinical
trials for novel and urgently-needed treatments for FOP. The International Clinical Council on FOP (ICC) was established in 2016
to provide consolidated and coordinated advice on the best practices for clinical care and clinical research for individuals who
suffer from FOP. The Clinical Trials Committee of the ICC developed a focused list of key considerations that encompass the
specific and unique needs of the FOP community – considerations that are endorsed by the entire ICC. These considerations
complement established protocols for developing and executing robust clinical trials by providing a foundation for helping to
ensure the safety of subjects with FOP in clinical research trials.
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Introduction
Clinical trials in orphan diseases are becoming increasingly
common. Orphan drug disease designations are one of the
fastest areas of growth. One such orphan disease,
fibrodysplasia ossificans progressiva (FOP; MIM#135100), is
characterized by widespread progressive heterotopic ossifica-
tion (HO) of skeletal muscle and soft connective tissues [1].
The course of FOP is cumulative, leading to progressive loss
of function and independence [2]. Furthermore, HO in FOP
can be spontaneous or be triggered by trauma and inflamma-
tory events throughout life [1–4]. Although HO is by far the
most prominent clinical feature in FOP, other organ systems
such as the central nervous system can also be affected [1, 5].
The unique phenotypes of FOP, as well as the high risk of
complications, pose significant challenges for clinical care
and clinical trial design that must be considered to optimize
subject safety. Here, we propose FOP-specific clinical trial
considerations that are agreed upon by international FOP
clinical experts.
Clinical manifestations of FOP
FOP is a severely disabling heritable disorder of connective
tissue characterized by the classic features of congenital
malformations of the great toes and progressive HO that
forms qualitatively normal bone in characteristic
extra-skeletal sites [2]. The worldwide prevalence is estimated
at 1/1 300 000 to 1/2 000 000 [6]. There are no ethnic, racial,
gender or geographic predilections to FOP. Children who
have FOP appear normal at birth except for congenital
malformations of the great toes. Radiological findings can as-
sist with diagnosis of the disease [7]. During the first decade of
life, sporadic episodes of painful soft tissue swellings (ʻflare-
upsʼ) occur spontaneously or can be precipitated by soft tissue
injury, intramuscular injections, viral infection, muscular
stretching, muscular fatigue or falls. These flare-ups
transform skeletal muscles, tendons, ligaments, fascia and
aponeuroses into heterotopic bone, progressively rendering
movement impossible. Classic FOP is caused by a recurrent
activating mutation (c.617G>A; p.R206H) in the gene
encoding Activin A receptor type I/Activin-like ki-
nase 2 (ACVR1/ALK2), a bone morphogenetic protein
(BMP) type I receptor [8]. There are a few patients with
exceedingly rare genetic variant forms of FOP [9] that may
show the classical phenotypic presentation, or more severe
phenotypes.
The diagnosis of FOP can easily be made by clinical evalu-
ation. Confirmatory genetic testing is available. Delayed diag-
nosis still occurs, despite the hallmark changes in great toes.
Differential diagnoses are varied but often include progressive
osseousheteroplasia (POH), osteosarcoma, lymphoedema, soft
tissue sarcoma, desmoid tumours, aggressive juvenile
fibromatosis, calcinosisof skinandmuscles, infectionandnon-
hereditary (acquired) heterotopic ossification. Although most
cases of FOP are sporadic (non-inherited mutations), a small
number of inherited FOP cases show germline transmission in
an autosomal dominant pattern.
At present, there are no definitive treatments for FOP, but
a brief, 4-day course of high-dose corticosteroids combined
with nonsteroidal anti-inflammatory drugs (NSAIDs), started
within the first 24 h of a flare-up, may help to reduce the in-
tense inflammation and tissue oedema seen in the early
stages of the disease [2]. Preventative management is based
on prophylactic measures against falls, respiratory decline
and viral infections. Themedian estimated lifespan is 56 years
[10]. Most patients are wheelchair bound by the end of the
second decade of life and commonly die of complications of
thoracic insufficiency syndrome [1, 10].
The dramatic presentation of FOP and growing under-
standing of the disease’s pathogenic mechanisms have
triggered strong and growing interest in clinical trials for
novel treatments in FOP. These studies have highlighted
the need for understanding the unique clinical features
of FOP and how they affect clinical trial design and
execution.
The International Clinical Council on FOP
(ICC)
The ICC was established in 2016 to provide consolidated and
coordinated advice on the best practices for clinical care and
clinical research for those who suffer from FOP. The founding
members are 19 internationally recognized physicians who
are clinical experts in FOP and who have a deep understand-
ing of the challenges and the needs of patients with FOP.
The missions of the ICC are:
• to educate on best practices for the care of individuals with
FOP;
• to advise on the design and conduct of interventional trials
in patients with FOP;
• to update the FOP clinical guidelines;
• to advocate for a robust infrastructure for data sharing and
collaboration on vital and emerging matters of clinical con-
cern to the FOP community;
• to identify less-explored areas of caring for patients with
FOP and issues that may drive insight into research;
• to share valuable clinical experiences from the care of pa-
tients with classic and variant FOP; and
• to better understand the variable phenotype of FOP and the
systemic nature of FOP pathology.
One of the key challenges identified by the ICC was the
need for FOP-specific guidelines to support the development
of safe and transformative treatments for patients with FOP
worldwide. The ICC seeks to provide research scientists at
university laboratories, pharmaceutical companies, biotech-
nology firms and government agencies with expert advice
on clinical research trials tailored to the FOP community.
Here, we discuss the major challenges and considerations
for successful clinical trials that are specific to the FOP
community. These considerations are meant to complement
the standard approaches for clinical trial design and
execution by highlighting considerations specific to the
FOP community.
Methods
We identified an unmet need for a consolidated collection of
clinical trial considerations directly relevant to the FOP
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community, with a particular focus on safety and clinical
trial procedures. The Clinical Trials Committee, composed
of eight experts in clinical trials and FOP clinical care, met
using a longitudinal round-table discussion format via web
conferences and in-person meetings. The committee
reviewed the clinical course and management of FOP in the
literature and in personal experience; the current treatment
guidelines [1]; current US Food and Drug Administration
(FDA) and European Medicines Agency (EMA) recommenda-
tions for the design of clinical trials; and discussed personal
experiences with clinical studies related to patients with
FOP. The committee focused on the four main steps of a
clinical trial (preclinical, trial design, trial execution and
post-trial evaluation) to identify areas where FOP-specific
considerations were particularly important, as they could
substantially affect the success of a trial and the safety of
subjects. These topic areas were reviewed by the full ICC,
which included 21 clinical experts in FOP and one patient
representative. The Clinical Trials Committee then consoli-
dated and further developed the recommendations. The
final considerations were then reviewed by the committee
and by the full ICC.
Results
The ICC Clinical Trials Committee identified challenges that
were important for both investigator-initiated and industry-
sponsored studies. In addition, the committee recognized
that these considerations are not exclusive, and that the con-
siderations are notmeant to be used to dictate specific clinical
trial design or methods, as those considerations are often
agent or location specific and best left to trial investigators.
Furthermore, the committee recognized that ongoing clinical
studies and improvements in clinical care will continue to re-
veal more FOP-specific considerations as our knowledge
about FOP disease pathogenesis improves. Thus, the Clinical
Trials Committee and the entire ICC sought to establish a
common foundation for discussions about critical consider-
ations that are specific to the FOP community.
Pre-clinical study development
Engage established experts in FOP clinical care, such as the
members of the ICC, as a resource during early study design.
Investigators and companies are encouraged to use the ICC
as an advisory resource for discussing trial design and
potential strengths/weaknesses of a particular study. The
ICC will not serve as a governing body or require ICC
approval for a study, as primary responsibility lies with the
primary investigators (PIs) and sponsor. The ICC will have
mechanisms for maintaining confidentiality.
Engage the FOP community, including patients with FOP, early
on in study design. Patients with FOP have unique
limitations and requirements for participating in a study.
Understanding these requirements early in the study design
process can help to maximize the success of a study and
safety for FOP participants.
Clinical studies should be based on preclinical rationales in model
systems. Trial rationales should be supported by appropriate
preclinical data in an appropriate preclinical model. This
could include demonstration of efficacy in established
genetic mouse models of FOP, with demonstration of in vitro
signalling or biological effects, as appropriate. Whenever
possible, assessment of non-HO effects should be included,
including but not limited to potential reproductive,
neurological, cardiac, pulmonary, gastrointestinal, growth
and developmental, oral/dental and haematological
complications.
Ideally, preliminary studies should include sufficient assessment in
humans for safety in an appropriate parallel population with age-
and sex-matched subjects. Ideally, human preliminary data
should be used to maximize safety. These should include
information in both sexes and in an appropriate age range
relevant to the study and potential follow-up studies.
Trial design
Use of the best possible clinical trial designs to assess potential
therapies. Formal clinical trials, performed in a way
consistent with future regulatory approval and with strong
scientific rigour, are the best way to determine the efficacy
and safety of any potential therapy. The small population of
patients with FOP necessitates careful planning, to ensure
that the results are as robust as possible.
All studies should have ethics committee approvals. All clinical
trials should obtain the approval of the applicable local
ethics committee and be scientifically validated before any
investigational therapy is given to a subject.
Pediatrics as the battleground. Trials that can include children
are encouraged, provided that the appropriate safety data,
indications and preliminary data are present and in
compliance with local regulations such as those proposed
by the European Commission [11]. Trials of medications
that may already be used in paediatric populations for other
conditions, and drugs that may be generic or of lower cost,
are of particular interest.
Protection for a vulnerable population. Patients with FOP are
considered disabled and are thus a vulnerable population.
Appropriate protections for consenting and data sharing
should be implemented. Genetics studies should have
adequate protections, given the extremely small population
of patients with FOP and the high risk of de-identification,
particularly when combined with imaging. All genetic
studies, such as those including DNA sequencing, RNA
sequencing and microbiome studies, need to be
appropriately de-identified and properly consented.
Likewise, imaging data, particularly whole-body imaging,
are unique to each subject and could allow de-identification
based on HO patterns.
Emphasis on safety. Trials need to be designed with subject
safety as the topmost priority. We encourage all companies
and research groups to share primary data from safety trials
directly with the investigators, and not rely solely on
Clinical trial considerations for FOP
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summary data often presented in investigator brochures. This
is particularly important for investigator-initiated studies, as
safety information may not be readily available or
scrutinized by regulatory agencies, such as the FDA or EMA.
We recognize that some of these data may be sensitive, so a
two-way nondisclosure agreement is preferable within the
project team. We also encourage investigators to use the
ICC as a resource to support and maintain safety.
FOP-specific health considerations should be included in trial
design and safety assessments. Key considerations unique to
FOP are listed below. These considerations, as well as study-
specific risks, should be clearly discussed with all subjects
with FOP.
a. Repeated blood draw/intravenous access compli-
cations: patients with FOP can tolerate peripheral blood
collection when performed carefully by an experienced
phlebotomist. It is critical that the procedure be performed
in as gentle and minimally invasive manner as possible.
Tourniquet time and number of blood draw attempts
should be minimized, according to the current FOP treat-
ment guidelines. Consultation with clinicians who are fa-
miliar with the care of patients with FOP is critical.
b. Respiratory complications: Patients with FOP are at
risk of restrictive lung disease because of chest wall HO,
congenital malformation of the costovertebral joints [1]
and possibly changes in lung physiology [12]. Patients with
FOP are also extremely difficult to intubate owing to
their cervical spine malformations, jaw involvement and
HO [1, 13]. Clinical trials should consider these risks, and
whether monitoring is needed. In addition, healthcare pro-
viders should be trained with a standard operating
procedure for managing patients with FOP in the event of
anaphylaxis or respiratory failure. These procedures should
include FOP-specific processes for intubation of the trachea,
following the current FOP treatment guidelines [1] and best
practices of airway management of patients with FOP [13].
c. Infection complications: Although patients with FOP
are not known to be at higher overall risk for infections, re-
spiratory infections can be especially devastating, given
the respiratory compromise present in affected patients
with FOP and the lack of immunizations [1]. Appropriate
management strategies, including the use of universal pre-
cautions and contact precautions, as well as prophylactic
medications such as oseltamivir (Tamiflu), should be
incorporated into study protocols as appropriate. In
addition, extra care should be taken to prevent hospital-
acquired infections. These are best documented with a
standard operating protocol for the team.
d. Gastrointestinal complications: Many patients with
FOP have decreased mobility of their jaw. In addition, a
number of patients with FOP report frequent nausea or
vomiting. This should be considered as vomiting in a
patient with FOP may be associated with a higher risk of
pulmonary aspiration. Limited jaw mobility may also
affect choice of how an oral medication is administered
(i.e. pill size, or need for powders or liquids). Monitoring
of maximal jaw opening, or assessments of salivary flow,
may be incorporated depending on the trial design and
pharmacological compound.
e. Neurological considerations: Patients with FOP have
reported a higher incidence of neurological concerns in-
cluding pain, both during and out of a FOP flare [1, 14].
In addition, some patients with FOP have neurological
changes, as seen on magnetic resonance imaging (MRI),
such as central nervous system demyelination [5];
however, the significance of these changes is unclear. Pain
measures should be included in any clinical trials, with
appropriate clinical management available for subjects.
f. Potential complications of blood pressure mea-
surements: Blood pressure measurements have been an-
ecdotally reported to be associated with the triggering of
FOP flares but clear correlation with flares has not been
studied systematically. Blood pressures should be taken as
infrequently as possible, in a manner that follows the cur-
rent FOP clinical guidelines [1]. Blood pressure should be
taken manually, with minimal cuff inflation, and with as
short of a duration of cuff inflation as necessary. Repeated
blood pressure measurements should be avoided when-
ever possible.
g. Radiology considerations: Although patients with
FOP have no known increase in complications from radia-
tion exposure, transportation to a radiology site and posi-
tioning for the appropriate imaging can be extremely
challenging because of the HO and body positioning. Sub-
jects, care givers and healthcare staff should be trained
about the limitations of mobility. Adequate soft padding
and safe transfer equipment should be provided to the ra-
diology team to position a subject properly for imaging. Fi-
nally, some subjects will not be able to be imaged owing to
their ankylosed joints. Clinical trials should consider this
at the time of enrolment and during the study, as a sub-
ject’s status may change over the duration of a study.
h. Mechanism for rapid response to a FOP flare-up:
FOP flares can occur spontaneously, with no clear trigger-
ing event. The standard operating protocol of all trials
should include mechanisms for rapid assessment, re-
sponse and treatment of potential FOP flare-ups to de-
crease the risk of HO formation.
i. Travel risks: As FOP affects joint mobility, patients with
FOP are at increased risk of injury during travel, particularly
in busy transportation hubs such as airports. Sufficient times
for transfers, as well as pre-arrangements for wheelchairs and
transport assistance, and the need for caregivers to travel
with subjects, should be discussed with any potential subject
and incorporated into the standard operating protocols for
clinical studies. Potential risks for physical strain should also
be considered at all steps along a travel route. In addition, the
screening of potential subjects for safety during travel (i.e.
the risk of respiratory failure during a long flight) should be
performed routinely as part of any trial.
Considerations for paediatric patients with FOP. Clinical trials
involving children should utilize a team with experience
in caring for paediatric patients with FOP. Study procedures,
such as phlebotomy and imaging, can be very difficult
and anxiety-provoking. In addition, some procedures
that are normally conducted with sedation or general
anaesthesia, such as imaging studies in very young children,
are associated with much higher risks in children with
FOP because of respiratory compromise, restricted neck
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movement, restricted jaw movement and anaesthesia risks in
patients with FOP (see respiratory complications in the ‘FOP-
specific health considerations’ section above). Clinical
studies should also be designed to consider the needs of
children, including prevention of fatigue, minimization of
procedures, using the lowest radiation doses possible,
minimizing the stresses of travel/time zone changes and
keeping days missed from school to a minimum. Additional
considerations for the families, including the need for
families to identify childcare support for younger siblings or
for the family to travel together, should be incorporated
into the study design. Finally, recognition of the specific
social/emotional needs of children and adolescents (such as
empowerment in decision making) can be extremely
valuable for successful trial execution in this subject
population [15].
International cooperation. Multinational trials are strongly
encouraged. This is important for recruitment but also for
spreading key resources and knowledge about FOP.
Although medical management is largely standardized
according to the FOP treatment guidelines [1], management
of FOP complications can vary significantly, based on the
availability of local resources (i.e. mobility devices,
management strategies and so forth).
Limited subject availability. As with other rare and orphan
diseases, trials need to be designed with an understanding
and appreciation of the very limited number of patients
with FOP in the world, as well as the even more limited
number of centres with the multidisciplinary clinical
expertise for successfully executing trials. Where and when
appropriate, subjects with non-ACVR1 R206H variants of
FOP should be included.
Innovative trial design. Placebo-controlled trials are
important for scientific integrity but can be challenging for
FOP families because of the rarity and severity of the
disease, and is likely to present ethical challenges once even
partially effective medications become available. We
encourage innovative trial designs, including randomized
trials with a crossover of the placebo group to active
treatment, use of annotated historical control data, and
non-inferiority designs using active comparators in studies
where efficacy has already been proven. We encourage trial
designs that allow subjects to continue on the medications
after the trial ends (i.e. open-label phase or other equivalent
system) if the medications show evidence of efficacy. This is
especially important in less-resourced countries where
post-trial access to therapy may be a challenge because of
cost. As a result of new paediatric legislation in Europe and
North America, it is now customary for industry-sponsored
clinical trials with new medications to involve centres in
less-resourced countries [11].
Common study endpoints. Data, including those derived
from subjects who receive placebo or are in observational
studies, should have common assessments and outcome
measures. Plans should be established for the raw data to be
shared whenever possible [i.e. via the International FOP
Association (IFOPA) registry]. This will help to maximize the
impact from the small number of subjects by allowing for
direct comparisons of outcomes. It will also increase the
number of subjects that could be used as a virtual control
arm, particularly as treatment-naive subjects become less
common. These common assessments should include the
following:
a. A core set of baseline data should be obtained, cover-
ing baseline patient characteristics (i.e. demographics,
extent of HO, functional status, associated FOP features,
genetic variants, and pain assessments) and baseline
flare-up activity (i.e. frequency, duration, locations and
flare symptoms).
b. Common assessments of the investigational agent
should be collected, including but not limited to the effect
on frequency of flares, extent of established and new HO,
functional assessments and tolerability/toxicity of the
agent concerned.
c. Functional assessment should include the cumulative
analogue joint involvement scale (CAJIS) [16], assessed
by a physician.
d. Patient-reported outcomes should include activities
of daily living and quality of life assessments [such as the
FOP Independent Activity of Daily Living (FOP I-ADL)
Questionnaire or FOP-Physical Function Questionnaire
(FOP-PFQ) and EuroQol 5 dimensions questionnaire with
a three-level scale (EQ-5D-3 L)].
e. Volumetric measurements of ossification via total
body (preferred) or site-specific new HO by low-dose com-
puted tomography (CT) should be included. This will also
allow quantitation of bone formation. Other related as-
sessments, such as 18F sodium fluoride positron emission
tomography (PET)/CT can also be considered [17, 18];
however, availability may be limited in some institutions.
f. Where alternate scores ormeasures are used, these
need to be demonstrated to be at least equivalent
in performance to the recommendedmeasures, and ide-
ally have known and close correlation with the recom-
mended measures.
Clinical trial execution
Sufficient resources should be allocated for execution of the
study. People affected by FOP have unique needs and often
do not travel frequently owing to their high care needs. In
addition, sufficient resources for robust documentation,
consistency and high data quality are important for all
studies, following international and local medical and
ethical standards. We recommend close consultation with
FOP expert centres, the ICC and the FOP community, to
make sure that assessments are practical, safe and will yield
usable data.
Travel considerations. The transportation of a patient with
FOP involves many factors. Pretrial assessment may require
close coordination with the local physicians and FOP experts,
particularly if there is a risk of respiratory compromise, as
patients with FOP are at increased risk of complications from
hypoxia, injury and fatigue [1, 19]. Appropriate medical
management teams should be available on site to assist with
potential complications. Appropriate caregivers should be
allowed to travel with the subjects on site (usually one or two
Clinical trial considerations for FOP
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caregivers) for routine assistance, as well as injury prevention
during travel. Specific travel considerations are discussed below.
a. Travel seating: Patients with FOP have a limited range of
motion, limbs fixed in awkward positions and areas of
heterotopic bone that may be protruding. Seating in aircraft,
trains or other vehicles should accommodate these by
providing sufficient padding, comfort and support, includ-
ing those customized for or currently used by the FOP
subject. In addition, rest breaks should be provided, to mini-
mize the risks of developing pressure sores and deep vein
thrombosis. Whenever possible, transport in the patients’
own wheelchair should be accommodated, as this often has
the best support to minimize fatigue and injury.
b. Hotels and lodging must be Americans with Dis-
abilities Act (ADA) accessible: Although some hotels
are considered ADA accessible, they may not be fully com-
patible with motorized wheelchairs or patients with FOP
(i.e. located at the top of a hill or unable to accommodate
subjects with significant physical deformities such as
outstretched extremities). Prescreening of facilities and
asking the subjects for details about their needs can be very
helpful for visit planning.
c. Trial visits: Fatigue is a major issue for patients with FOP.
Consideration for preventing subject fatigue (i.e. by mini-
mizing travel or by scheduling half-day assessments with
sufficient rest) are important for reducing injuries or flares
related to the trial visit.
d. Blood draws in patients with FOP can be difficult
owing to poor venous access, contractures and unusual
positioning. A consistent, experienced phlebotomy team
experienced with patients with FOP is critical for success.
This includes any outpatient or home care blood draws.
Use of a vein finder/ultrasound can be extremely helpful.
Documentation of prior attempted and successful
phlebotomy sites, and any complications related to blood
draws, is beneficial for maximizing safety. In addition,
established protocols for minimizing phlebotomy and
trauma are critical (including a recommended tourniquet
time of less than 1 min to minimize risks of hypoxia).
e. Considerations for childrenwith FOP: Fasting blood
draws are extremely difficult and anxiety provoking. Child
Life Services should be engaged whenever possible, and
needle desensitization training [20] under the care of an
experienced professional should be considered if available.
Imaging with ionizing radiation should be kept to a
minimum owing to risks in all paediatric populations
[21]. Procedures that place children with FOP at additional
risk (such as the use of general anaesthesia for imaging, or
increased risk of fatigue from long clinic visits or multiple
sequential assessments) should be carefully planned or
minimized whenever possible.
f. MRI, CT and PET/CT scanning optionsmay be lim-
ited owing to contractures and HO. Careful and cre-
ative positioning may be needed (i.e. scanning cranial
and caudal portions separately). MRIs may not be possible,
depending on the nature of the contractures or immobil-
ity. We recommend considering obtaining subject photo-
graphs prior to arrival and screening, so that the
positioning or suitability of an imaging modality can be
assessed beforehand. Imaging facilities should have plans
in place for safe transfer of subjects onto the imaging table
(lifts or dedicated lift teams).
Subjects and accompanying care providers should have adequate
health and travel insurance. This is critical, as subjects with
FOP are at high risk of complications from any injury with
transportation, and of a worsening of any flares due to
travel injuries or fatigue. Appropriate medical insurance
that is effective at all points along the travel route should be
provided, with the ability to cover pre-existing conditions
(i.e. those related to FOP). This should be explicitly
described to the potential subject. International patients are
particularly vulnerable, given differences in coverage in
their host country, as well as longer or more challenging
travel requirements.
Post-clinical trial
Timely publication/data release. Trials should have a plan for
rapid public release of data, both positive and negative. This
is critical for the safety of patients and for the scientific
integrity of the field. All clinical trials should include rapid
adverse event recording and the sharing of findings
whenever possible.
Cooperation for the benefit of the patients. We strongly
encourage companies and all researchers to work with each
other to the highest extent possible, including the sharing
of baseline data, assessment tools and patient care
experiences, as the number of subjects available for trials is
extremely limited, and also because any major adverse event
(i.e. death or disability) will have a major negative impact on
all trials in the FOP arena.
Shared common data elements. Clinical trials should be
designed to support ancillary observational trials, whenever
possible (i.e. of baseline data). Trials should be performed
with the assumption that the data collected and findings
made will be maximally shared. Shared common data
elements and endpoints are encouraged, such as
quantitation of total HO, functional assessments (e.g. CAJIS
score) and serum biomarkers. In addition, common data
elements following public guidelines, such as through the
National Institutes of Health (NIH) Common Data Element
Initiative (https://www.nlm.nih.gov/cde/glossary.html) or
shared elements with the IFOPA patient registry, are
strongly encouraged.
Data deposition at end of trial. We encourage discussion with
the IFOPA to leverage the global patient registry as a potential
point for data sharing, particularly of placebo or baseline
results that will be important for understanding the natural
history of the disease. We also encourage public release of
the raw data (such as sequencing data) following guidelines
of large public agencies such as the NIH (https://grants.nih.
gov/policy/sharing.htm) and using public repositories. This
should be done at the time of publication, so that the field
can benefit and potentially decrease risk to the patients
with FOP.
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Postmarketing/post-trial surveillance should be conducted for all
agents. Many countries already require postmarketing
studies for orphan drugs. However, all therapies tested in
both investigator-initiated and industry-sponsored studies
should have a procedure for long-term postmarketing or
post-trial follow-up, to ensure the long-term safety and
efficacy of the treatments. It is important to show how
functional mobility changes over the long term since
differences may not be readily detected in the shorter
studies used for drug approvals. These longitudinal
assessments should be implemented into the long-term
postmarketing assessments.
Long-term access to effective experimental medications should be
developed if possible and appropriate. Mechanisms for access
to an effective experimental medication via a
compassionate use programme or follow-up studies should
be developed whenever possible. Consideration for less-
resourced countries should be incorporated into the
postclinical trial plan.
Leftover biospecimens should be shared whenever possible.
Clinical trials provide a rare opportunity to study large
numbers of patients with FOP together. Whenever possible,
leftover biospecimens with appropriate annotations (but de-
identified) should be made available for other researchers.
This should be included in the consenting process.
Discussion
The recent interest in clinical trials for novel treatments for
FOP is an exciting development for this rare but extremely se-
vere disease. During the past few years, this interest has led to
recognition that there needs to be a better understanding of
the unique challenges that patients with FOP face in clinical
trials. Understanding the social, emotional and disease con-
text of each patient group can help to improve trial design
and safety. This global approach is similar to the World
Health Organization’s International Classification of Func-
tioning, Disability and Health framework [22]. Here, we iden-
tified the major considerations for clinical trials in FOP,
including disease-specific factors such as risks of injury from
trauma and unique requirements for transportation, as well
as how the rare nature of FOP affects clinical trial design
and execution. As in all clinical studies, subject safety takes
utmost priority and should include a full consent process that
allows for voluntary participation without coercion.
The results of our discussion among 21 clinical experts in
FOP and one family representative allowed us to develop a
strong consensus statement with key considerations for ef-
fective clinical trials in FOP. One major challenge that the
ICC identified was the small number of clinicians with expe-
rience of caring for significant numbers of patients with FOP.
This resource bottleneck meant that many investigators may
have conflicts of interest related to their work in clinical
trials, but would otherwise be highly qualified to serve in
advisory roles. This is similar to other areas of rare-disease re-
search. The ICC felt that open, early and public declaration
of these potential conflicts, and the avoidance of
anonymous consultations (i.e. via third-party data gathering
companies, where potential conflicts cannot be identified),
was the best strategy for promoting knowledge and safety
in FOP-related clinical studies. An ethics committee within
the ICC was constituted to support this open strategy.
Another major challenge that the ICC identified was
the difference between investigator-initiated and industry-
sponsored clinical trials – an area that has been explored
in many disciplines [23]. Although trials that are designed
to support a drug approval or application process must also
follow established regulatory guidelines, other trials that
are smaller or exploratory may be more limited in scope
and resources. Our committee recognized that there are
strengths and limitations in all formats of trials [24], but
that investigator-initiated trials should also strive to meet
similar standards for data quality and subject safety to
larger trials or those sponsored by industry. Likewise, all
clinical trials involving patients with FOP should take into
account the increased resources and effort needed for safe
and successful enrollment of subjects with FOP. Finally,
we firmly believe that strong cooperation between aca-
demics, industry, clinicians and patient support groups is
absolutely critical for developing effective therapies for
this devastating disease.
These guidelines are not exclusive or comprehensive. They
are not meant to be used to dictate specific clinical trial design
or methodology – those types of concerns are often agent- or
location-specific and best left to trial investigators. Rather, the
ICC seeks to establish a common foundation for discussions
about critical considerations that are specific to the FOP
community, with the main focus being patient safety. Together,
we believe that these FOP-specific considerations, along with
established processes for robust and safe clinical trials, will help
to enhance FOP subject safety and maximize clinical trial result
yield for the entire FOP community.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY [25], and are
permanently archived in the Concise Guide to PHARMA-
COLOGY 2017/18 [26].
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